Jonsson Comprehensive Cancer Center
ucla.eduTotal trials
393
Active
114
Phase 3
19
Total enrollment
436,947
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 83 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| temozolomide | — | — | — | 10 | |||
| Ferumoxytol | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | 10 | |||
| carboplatin | — | — | 13 | ||||
| Durvalumab | — | — | — | — | — | 4 | |
| Lutetium Lu 177 Vipivotide Tetraxetan | — | — | — | — | — | 3 | |
| cisplatin | — | — | — | 7 | |||
| Docetaxel | — | — | — | 6 | |||
| Fluorouracil | — | — | 6 | ||||
| fludarabine phosphate | — | — | — | — | 9 | ||
| Osimertinib | — | — | — | — | — | 3 | |
| Leucovorin | — | — | — | 3 | |||
| Oxaliplatin | — | — | — | 3 | |||
| Tremelimumab | — | — | — | — | — | 3 | |
| Fisetin | — | — | — | — | — | 2 | |
| Abemaciclib | — | — | — | — | — | 2 | |
| Apalutamide | — | — | — | — | — | 2 | |
| trametinib | — | — | — | — | — | 2 | |
| Anastrozole | — | — | — | — | — | 2 | |
| cyclophosphamide | — | — | 10 | ||||
| paclitaxel | — | — | — | 9 | |||
| trastuzumab | — | — | 8 | ||||
| Leucovorin Calcium | — | — | — | 3 | |||
| aldesleukin | — | — | — | — | 6 | ||
| bevacizumab | — | — | — | — | — | 5 | |
| dasatinib | — | — | — | — | 4 | ||
| NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL | — | — | — | — | 3 | ||
| dendritic cell vaccine therapy | — | — | — | — | 3 | ||
| Letrozole | — | — | — | — | 2 | ||
| Irinotecan | — | — | — | — | 2 | ||
| Liposome-encapsulated Daunorubicin-Cytarabine | — | — | — | — | 2 | ||
| Enfortumab Vedotin | — | — | — | — | — | 1 | |
| Fulvestrant | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| Ribociclib | — | — | — | — | — | 1 | |
| Tucatinib | — | — | — | — | — | 1 | |
| Talazoparib | — | — | — | — | — | 1 | |
| Imlunestrant | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Niraparib | — | — | — | — | — | 1 |
43 more active programs hidden
Next readouts
- 2023-12-05
- 2024-01-31
- 2024-09-01
- 2024-09-23
- 2024-10-11
- 2025-06-24
- 2025-12-01
- 2026-01-11
- 2026-01-27
- 2026-05-22
Top conditions
- Prostate Cancer30
- Lymphoma24
- Breast Cancer22
- Lung Cancer21
- Leukemia17
- Brain and Central Nervous System Tumors16
- Unspecified Adult Solid Tumor, Protocol Specific16
- Prostate Adenocarcinoma12
Frequently asked questions about Jonsson Comprehensive Cancer Center
- How many clinical trials does Jonsson Comprehensive Cancer Center have on ClinicalTrials.gov?
- Jonsson Comprehensive Cancer Center is listed as the lead sponsor on 393 clinical trials in ClinicalTrials.gov, 114 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Jonsson Comprehensive Cancer Center's trials are in Phase 3?
- 19 of Jonsson Comprehensive Cancer Center's trials are in Phase 3, spread across 83 active drug programs.
- What therapeutic areas does Jonsson Comprehensive Cancer Center focus on?
- Jonsson Comprehensive Cancer Center's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Lymphoma, Breast Cancer, Lung Cancer, Leukemia.
- When are Jonsson Comprehensive Cancer Center's next clinical trial readouts?
- Jonsson Comprehensive Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer”, expected around 2023-12-05.